Latest News About Charm

Here are the latest publicly available updates on Charm Therapeutics:

• Charm Therapeutics announces key leadership and financing news in 2025. Notably, Dr. Erkut Bahceci was appointed Chief Medical Officer in September 2025, following an $80 million Series B aimed at advancing their AI-designed menin inhibitor for AML. This is based on their press releases and archived news summaries from late 2025 [CHARM Therapeutics press releases, 2025-09-08; 2025-09-02].[1][2]

• The company reported progress on CHM-029, their next-generation menin inhibitor, including preclinical data suggesting activity against resistance mutations and plans for first-in-human studies. These updates appeared in conjunction with their September 2025 Series B coverage and follow-on press activity in 2025 [CHARM Therapeutics press releases, 2025-11-13; 2025-09-02].[2]

• Earlier in 2025, CHARM continued broad communications around its AI-driven approach to drug discovery, reinforcing its focus on AML and leveraging DragonFold AI technologies disclosed in prior funding announcements and corporate news pages [CHARM Therapeutics 2024–2025 news archive].[1]

Illustrative example of what this means:

• If you’re tracking AML-focused biotech, Charm’s 2025 moves signal a push from discovery toward early clinical evaluation for a first-in-class menin inhibitor, with leadership bolstering clinical development and partnerships that may enable faster trials. This interpretation aligns with their public statements announcing the Series B and executive appointment in 2025.[2][1]

Would you like a concise timeline of Charm Therapeutics’ 2024–2025 announcements with direct links to each press release, or a summary of CHM-029 preclinical data and its anticipated clinical path? I can gather and organize those details for you.[1][2]